Eaton Vance Management Gilead Sciences, Inc. Transaction History

Eaton Vance Management

$67.5 Billion
Q3 2022

A detailed history of Eaton Vance Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Eaton Vance Management holds 2,089,904 shares of GILD stock, worth $193 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

2,089,904

Previous 2,066,819 1.12%

Holding current value

$193 Million

Previous $128 Million 0.92%

% of portfolio

0.19%

Previous 0.18%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $1.37 Million - $1.57 Million	23,085 Added 1.12%	2,089,904 $129 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $5.65 Million - $6.36 Million	97,882 Added 4.97%	2,066,819 $128 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $16.9 Million - $21.2 Million	291,520 Added 17.38%	1,968,937 $117 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $208,135 - $236,237	-3,208 Reduced 0.19%	1,677,417 $121 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $1.79 Million - $1.93 Million	26,434 Added 1.6%	1,680,625 $116 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $241,312 - $263,668	3,802 Added 0.23%	1,654,191 $114 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $622,020 - $709,724	10,367 Added 0.63%	1,650,389 $107 Million
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $1.69 Million - $1.93 Million	-29,842 Reduced 1.79%	1,640,022 $95.5 Million
Q3 2020 Nov 13, 2020	BUY	$62.1 - $78.08 $1.54 Million - $1.94 Million	24,808 Added 1.51%	1,669,864 $106 Million
Q2 2020 Nov 20, 2020	SELL	$72.34 - $84.0 $4.44 Million - $5.16 Million	-61,389 Reduced 3.6%	1,645,056 $127 Million
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $55.1 Million - $63.9 Million	-761,223 Reduced 30.85%	1,706,445 $131 Million
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $60.8 Million - $77.9 Million	-971,202 Reduced 28.24%	2,467,668 $184 Million
Q4 2019 Feb 11, 2020	SELL	$61.62 - $67.78 $9.59 Million - $10.6 Million	-155,679 Reduced 4.33%	3,438,870 $223 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $22.9 Million - $25.3 Million	-365,972 Reduced 9.24%	3,594,549 $228 Million
Q2 2019 Nov 21, 2019	BUY	$61.87 - $69.38 $1.08 Million - $1.21 Million	17,381 Added 0.44%	3,960,521 $268 Million
Q2 2019 Aug 16, 2019	BUY	$61.87 - $69.38 $10.9 Million - $12.2 Million	176,287 Added 4.68%	3,943,140 $266 Million
Q1 2019 May 14, 2019	BUY	$62.53 - $70.05 $12.5 Million - $14 Million	200,022 Added 5.61%	3,766,853 $245 Million
Q4 2018 Feb 07, 2019	SELL	$60.54 - $79.0 $12.5 Million - $16.3 Million	-205,963 Reduced 5.46%	3,566,831 $223 Million
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $8.11 Million - $8.98 Million	113,738 Added 3.11%	3,772,794 $291 Million
Q2 2018 Aug 10, 2018	SELL	$64.88 - $75.68 $17.6 Million - $20.5 Million	-271,518 Reduced 6.91%	3,659,056 $259 Million
Q1 2018 May 07, 2018	SELL	$72.84 - $88.8 $28 Million - $34.1 Million	-384,494 Reduced 8.91%	3,930,574 $296 Million
Q4 2017 Feb 12, 2018	SELL	$71.15 - $83.52 $8.17 Million - $9.59 Million	-114,881 Reduced 2.59%	4,315,068 $309 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $319 Million - $379 Million	4,429,949	4,429,949 $359 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.

Account

Eaton Vance Management Gilead Sciences, Inc. Transaction History